- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05908682
Säkerhet för gravida försökspersoner som exponeras för Ibrexafungerp, inklusive spädbarnsutfall
En enarmad säkerhetsstudie av försökspersoner som exponerats för Ibrexafungerp under graviditeten, inklusive spädbarnsresultat upp till ett år
This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
This is a single-arm safety study which comprises an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age who were exposed to ibrexafungerp during pregnancy, or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, and are volunteering to take part in this study. Subjects will be monitored starting from exposure during pregnancy until one year after live delivery.
Information on pregnancy outcomes and complications as well as fetal/neonatal/infant outcomes will be collected during the timeframe described in the protocol.
Subjects can enroll in the study by calling the telephone number directly (1-888-982-7299) or through SCYNEXIS BREXAFEMME Pregnancy Study Webpage, OR her healthcare provider (HCP) can, with her consent, enroll her on her behalf.
Data will be collected both retrospectively and prospectively using a variety of questionnaire that will be completed by the representative based on interview with the subject and/or HCP
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Sanjeev Miglani, MD
- Telefonnummer: +91-9910533655
- E-post: sanjeev.miglani@awinsals.com
Studieorter
-
-
Vasant Vihar
-
New Delhi, Vasant Vihar, Indien, 110057
- Rekrytering
- AWINSA
-
Kontakt:
- Sanjeev Miglani, MD
- Telefonnummer: +91-9910533655
- E-post: sanjeev.miglani@awinsals.com
-
Huvudutredare:
- Sanjeev Miglani, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The study population will include women who were exposed to ibrexafungerp at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, volunteering to take part in this study.
Beskrivning
Inclusion Criteria:
-
Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp
-
Subject and/or parent/legal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule/completion of questionnaire and release of medical records
- Subject can be identified by the sponsor or HCP, in terms of confirmed pregnancy.
A self-reported pregnancy will be considered as confirmed pregnancy if the Urine Pregnancy Test (UPT) result is positive.
- A woman can self-enroll in the study or her healthcare provider (HCP), with her consent, can enroll her on her behalf.
Exclusion Criteria:
- Females who were not exposed to safety study medications during pregnancy
- Refusal to participate in the study
- An inability to provide an accurate medical history or give informed consent
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiv: OTHER
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Study Cohort
Subjects who have been treated with Brexafemme (Ibrexafungerp) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving the last dose of Brexafemme. |
This is not an interventional study |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Major Structural Defects
Tidsram: From Brexafemme exposure up to one year after birth
|
To collect and describe selected fetal/neonatal/infant outcomes (i.e., major and minor congenital malformations, small for gestational age, and postnatal growth and development) at birth and through up to the first year of life of infants born to women exposed to ibrexafungerp during the defined pregnancy exposure window |
From Brexafemme exposure up to one year after birth
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To collect and describe pregnancy outcomes
Tidsram: From Brexafemme exposure up to one year post birth
|
Live birth, spontaneous abortions, stillbirths, elective abortions, and preterm births |
From Brexafemme exposure up to one year post birth
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Munsjukdomar
- Stomatogena sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Infektioner
- Genitala sjukdomar, kvinnor
- Bakteriella infektioner och mykoser
- Vulva sjukdomar
- Vulvit
- Vaginit
- Mykoser
- Vaginala sjukdomar
- Candidiasis
- Candidiasis, vulvovaginal
- Vulvovaginit
- Candidiasis, oral
Andra studie-ID-nummer
- 222030
- SCY-078-401 (Annan identifierare: Scynexis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .